<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-71616" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Carbapenem-Resistant Enterobacterales</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Hayden Z.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hollingshead</surname>
            <given-names>Caitlyn M.</given-names>
          </name>
          <aff>The University of Toledo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kendall</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>Providence</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hayden Smith declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Caitlyn Hollingshead declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Kendall declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-71616.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Antimicrobial resistance is a growing global problem. The increasing antimicrobial resistance of&#x000a0;<italic toggle="yes">Enterobacterales</italic> limits treatment options to combat infection. Carbapenems are commonly used for infections involving multidrug-resistant organisms. Unfortunately, some bacteria have developed mechanisms that inactivate this class of antibiotics. These organisms are known as carbapenem-resistant <italic toggle="yes">Enterobacterales</italic> (CRE). CRE are defined by resistance to at least 1 carbapenem or the presence of a carbapenemase. Mechanisms of carbapenem resistance include carbapenemase production, efflux pumps, or decreased porin expression. The development of carbapenem resistance underscores the importance of developing new antibiotics and effective stewardship of antibiotics currently in use. This activity outlines the evaluation and management of CRE infections and reviews the role of the interprofessional healthcare team in evaluating, treating, and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Select appropriate treatment options for a patient with carbapenem-resistant <italic toggle="yes">Enterobacterales</italic> infections.</p></list-item><list-item><p>Identify the reasons for a delayed diagnosis of carbapenem-resistant bacterial infections.</p></list-item><list-item><p>Compare the different mechanisms of carbapenem resistance.</p></list-item><list-item><p>Implement effective collaboration and communication among the interprofessional team to improve outcomes for patients affected by carbapenem-resistant bacterial infections.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=71616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=71616">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-71616.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Antibiotic resistance is a growing problem. Resistance exists for all known antibiotics,&#x000a0;and multi-drug resistant (MDR) pathogens are becoming more common.<xref ref-type="bibr" rid="article-71616.r1">[1]</xref><xref ref-type="bibr" rid="article-71616.r2">[2]</xref>&#x000a0;There are fewer new antimicrobials in the pipeline to combat antimicrobials that have developed resistance.<xref ref-type="bibr" rid="article-71616.r3">[3]</xref> Gram-negative bacteria have developed the broadest spectrum of resistance due to multiple structural adaptations and antibiotic degradation enzymes called beta-lactamases.<xref ref-type="bibr" rid="article-71616.r4">[4]</xref> Some of these antibiotic degradation enzymes include extended-spectrum beta-lactamases (ESBL), which are enzymes that hydrolyze penicillins, third-generation cephalosporins, and monobactams; AmpC beta-lactamases, which can hydrolyze most penicillins, a wide array of cephalosporins, and most beta-lactam beta-lactamase combinations; and carbapenemases, which can hydrolyze carbapenems and a wide variety of other beta-lactams.<xref ref-type="bibr" rid="article-71616.r4">[4]</xref><xref ref-type="bibr" rid="article-71616.r5">[5]</xref>&#x000a0;The presence of each of these has significant implications for antimicrobial selection.</p>
        <p>Carbapenemase-producing <italic toggle="yes">Enterobacterales</italic> (CRE) are of particular concern as they either possess a carbapenemase, a beta-lactamase capable of hydrolyzing antibiotics in the carbapenem class, or display resistance to a carbapenem in which the organism is not intrinsically resistant.<xref ref-type="bibr" rid="article-71616.r6">[6]</xref><xref ref-type="bibr" rid="article-71616.r4">[4]</xref>&#x000a0;Carbapenems are broad-spectrum and are typically reserved for treating MDR pathogens.<xref ref-type="bibr" rid="article-71616.r7">[7]</xref>&#x000a0;Structurally, carbapenems are similar to penicillins but have the addition of a pyrroline ring.<xref ref-type="bibr" rid="article-71616.r8">[8]</xref> Both antibiotics degrade the bacterial cell wall at the penicillin-binding protein via a beta-lactam ring; however, adding a pyrroline ring protects the beta-lactam ring from some degrading enzymes produced by the bacterium.<xref ref-type="bibr" rid="article-71616.r8">[8]</xref> CRE have developed resistance mechanisms against carbapenems, which has severe implications for the individual patient and hospital epidemiology.<xref ref-type="bibr" rid="article-71616.r4">[4]</xref></p>
        <p>Specialized knowledge is required when diagnosing, treating, and preventing CRE infections. Antimicrobial resistance is a dynamic and rapidly changing topic, and staying informed on the latest data regarding resistance is imperative to maintain excellent patient care. Maintaining excellent antimicrobial stewardship practices is imperative to decreasing rates of CRE in our communities.<xref ref-type="bibr" rid="article-71616.r9">[9]</xref> Bacteria may have multiple resistance mechanisms to carbapenems, but the most common is carbapenemase enzyme production.<xref ref-type="bibr" rid="article-71616.r10">[10]</xref><xref ref-type="bibr" rid="article-71616.r11">[11]</xref><xref ref-type="bibr" rid="article-71616.r12">[12]</xref>&#x000a0;These carbapenemase-producing carbapenem-resistant <italic toggle="yes">Enterobacterales</italic> use diverse mechanisms to degrade antibiotics.<xref ref-type="bibr" rid="article-71616.r6">[6]</xref> Other resistance mechanisms include increased efflux pump action and specific porin blocking at the bacterial cell membrane to limit the antibiotics' permeability, rendering them ineffective as they cannot access the bacterial cell.<xref ref-type="bibr" rid="article-71616.r4">[4]</xref></p>
      </sec>
      <sec id="article-71616.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Beta-lactamases are commonly grouped according to the Ambler classification system.<xref ref-type="bibr" rid="article-71616.r13">[13]</xref> Beta-lactamases in different classifications work via differing mechanisms.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Carbapenemase enzymes can be categorized into Ambler classes A, B, and D.&#x000a0;(see <bold>Image.&#x000a0;</bold>Carbapenemase&#x000a0;Ambler Classes).<xref ref-type="bibr" rid="article-71616.r13">[13]</xref></p>
        <p>
<bold>Class A Carbapenemases</bold>
</p>
        <p>The most common class A carbapenemases include <italic toggle="yes">Klebsiella pneumoniae</italic> carbapenemase (KPC), imipenem-hydrolysing beta-lactamase (IMI), non-metallo carbapenemase of class A (NMC-A), Guyana extended-spectrum beta-lactamase (GES), and <italic toggle="yes">Serratia marscescens</italic> enzyme (SME).<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Class A carbapenemases possess a serine amino acid at their binding sites and are characterized by their ability to hydrolyze penicillins, cephalosporins, carbapenems, and aztreonam.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> KPC is the most prevalent carbapenemase gene amongst all carbapenemase-producing CRE&#x000a0;and is the most commonly found in the United States.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref><xref ref-type="bibr" rid="article-71616.r15">[15]</xref></p>
        <p>
<bold>Class B Carbapenemases</bold>
</p>
        <p>Class B is defined by metallo-beta-lactamase (MBL) structures.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> This class possesses amino acids in the binding site that bind to zinc.<xref ref-type="bibr" rid="article-71616.r16">[16]</xref> These enzymes include NDM (New Delhi metallo-lactamase), IMP (Imipenem-resistant Pseudomonas), and VIM (Verona integron-encoded metallo-lactamase).<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Most class B carbapenemases hydrolyze all beta-lactams except for aztreonam.<xref ref-type="bibr" rid="article-71616.r16">[16]</xref> These carbapenemases are usually found on plasmid vectors and other transposable elements, allowing them to spread between bacteria.<xref ref-type="bibr" rid="article-71616.r16">[16]</xref> Due to a high sequence variability of 15%&#x000a0;to 70%, these enzymes are difficult to detect with molecular testing, slowing investigations to more fully understand their prevalence.<xref ref-type="bibr" rid="article-71616.r15">[15]</xref></p>
        <p>
<bold>Class D Carbapenemases</bold>
</p>
        <p>Oxacillin-hydrolyzing carbapenemase (OXA) enzymes make up class D carbapenemases.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Like class A carbapenemases, class D carbapenemases also include a serine amino acid at their binding sites.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> They differ from class A carbapenemases as they have decreased hydrolyzing activity against carbapenems and penicillins,&#x000a0;have no activity against extended-spectrum cephalosporins, and are not inhibited by older beta-lactamase inhibitors (eg, clavulanic acid, tazobactam, or sulbactam).<xref ref-type="bibr" rid="article-71616.r14">[14]</xref><xref ref-type="bibr" rid="article-71616.r17">[17]</xref><xref ref-type="bibr" rid="article-71616.r18">[18]</xref><xref ref-type="bibr" rid="article-71616.r17">[17]</xref> However, most are inhibited by avibactam.<xref ref-type="bibr" rid="article-71616.r17">[17]</xref> These genes are genetically similar to ESBL genes, thus making them difficult to differentiate from other ESBL producers on molecular testing.<xref ref-type="bibr" rid="article-71616.r12">[12]</xref>&#x000a0;OXA-48 is the most common isolate in this class and is typically found in <italic toggle="yes">Klebsiella pneumoniae</italic>.</p>
      </sec>
      <sec id="article-71616.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>KPC has emerged as the most common carbapenemase-producing CRE.<xref ref-type="bibr" rid="article-71616.r19">[19]</xref>&#x000a0;KPC is considered endemic in several regions, including the United States, Mexico, Portugal, Italy, Israel, and Greece, reflecting its establishment in bacterial populations of these areas.<xref ref-type="bibr" rid="article-71616.r20">[20]</xref> Oxa-48-like carbapenemases have gained a footprint in the Middle East, North Africa, and much of Europe, while NDM carbapenemases are prevalent in South Asia, the Mediterranean, Romania, Denmark, and Poland.<xref ref-type="bibr" rid="article-71616.r18">[18]</xref><xref ref-type="bibr" rid="article-71616.r21">[21]</xref><xref ref-type="bibr" rid="article-71616.r22">[22]</xref> IMP carbapenemases are notably present in the Asia-Pacific region, including Australia, China, and Japan, while Oxa-48-like carbapenemases are commonly found in Turkey.<xref ref-type="bibr" rid="article-71616.r22">[22]</xref>&#x000a0;The frequent movement of populations across borders can facilitate the movement of different carbapenemases to different regions.<xref ref-type="bibr" rid="article-71616.r22">[22]</xref></p>
        <p>Molecular testing, such as PCR, has been the most effective way of understanding the epidemiology and spread of carbapenemase-producing CRE.<xref ref-type="bibr" rid="article-71616.r22">[22]</xref>&#x000a0;This testing modality can identify specific strains of CRE and map their range within a hospital or worldwide. Genetic variability in carbapenemase genes may hinder the molecular identification of CRE strains, which could cause phenotypic resistance that is missed by assays that detect specific gene sequences.<xref ref-type="bibr" rid="article-71616.r23">[23]</xref></p>
        <p>Patients usually acquire carbapenemase-producing CRE infections in the hospital and long-term care facilities.<xref ref-type="bibr" rid="article-71616.r24">[24]</xref>&#x000a0;The majority of these patients have a long history of healthcare facility exposure due to unrelated diagnoses. If a patient is found to have a CRE infection, healthcare personnel need to utilize proper infection control protocols to prevent localized outbreaks.<xref ref-type="bibr" rid="article-71616.r25">[25]</xref></p>
      </sec>
      <sec id="article-71616.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The prototypical beta-lactam antibiotic, penicillin G, consists of a beta-lactam ring, thiazolidine ring, and an R group, or side chain.<xref ref-type="bibr" rid="article-71616.r26">[26]</xref> R groups help to determine the spectrum of activity of the antibiotic, help to protect against beta-lactamases, and determine some pharmacokinetic properties of the antibiotic.<xref ref-type="bibr" rid="article-71616.r26">[26]</xref> Penicillin impairs the function of the bacterial cell wall at the penicillin-binding protein (PBP) by preventing the transpeptidation of peptidoglycan, leading to the breakdown of the cell wall and eventual destruction of the organism.<xref ref-type="bibr" rid="article-71616.r26">[26]</xref> The synthesis of beta-lactamases can induce bacterial resistance to antibiotics.<xref ref-type="bibr" rid="article-71616.r27">[27]</xref> These enzymes hydrolyze the amide bonds in the beta-lactam rings.<xref ref-type="bibr" rid="article-71616.r27">[27]</xref> Other beta-lactam antibiotics, such as cephalosporins or carbapenems, have a similar mechanism of action at the PBP.<xref ref-type="bibr" rid="article-71616.r28">[28]</xref><xref ref-type="bibr" rid="article-71616.r8">[8]</xref> Still, the addition of different R groups on the adjacent thiazolidine ring and the addition of a pyrroline ring in the instance of carbapenems helps to shield against beta-lactamases, increase affinity for the PBP, and increase the stability of the antibiotic without hindering antimicrobial activity.<xref ref-type="bibr" rid="article-71616.r29">[29]</xref> Carbapenemases overcome these obstacles, rendering the antibiotic susceptible to degradation.<xref ref-type="bibr" rid="article-71616.r30">[30]</xref></p>
        <p>Pathogenic bacteria have gained the ability to circumvent carbapenem hydrolysis through intrinsic and acquired mechanisms.<xref ref-type="bibr" rid="article-71616.r31">[31]</xref> These mechanisms include enzymatic inactivation, porin selectivity, and efflux pumps.<xref ref-type="bibr" rid="article-71616.r31">[31]</xref> The earliest instances of carbapenem resistance appeared in bacteria with inherent resistance. <italic toggle="yes">Aeromonas hydrophilia, Serratia marcescens, and Enterobacter cloacae</italic> were some of the first environmental organisms discovered to resist carbapenem.<xref ref-type="bibr" rid="article-71616.r32">[32]</xref> Plasmids play a prominent role in the propagation of carbapenem resistance.<xref ref-type="bibr" rid="article-71616.r33">[33]</xref></p>
        <p>Carbapenems require transport into the bacterial intermembrane space via outer membrane proteins (OMPs), also known as porin channels, to reach the PBP.<xref ref-type="bibr" rid="article-71616.r29">[29]</xref> Thus, the loss of porin channels decreases the drug's ability to reach its site of action.<xref ref-type="bibr" rid="article-71616.r31">[31]</xref> Efflux pumps work in this space to remove the irregular or hostile molecules and antibiotics, further regulating the intramembrane environment.<xref ref-type="bibr" rid="article-71616.r31">[31]</xref> Non-carbapenemase-producing CRE resistance mechanisms act in this space to prevent access to the PBP and do not produce a carbapenem-specific beta-lactamase.<xref ref-type="bibr" rid="article-71616.r12">[12]</xref> Generally, efflux pumps and porin mutations do not confer high-level carbapenem resistance and usually help to confer resistance by coexisting with carbapenemases.<xref ref-type="bibr" rid="article-71616.r31">[31]</xref> In some strains, <italic toggle="yes">Pseudomonas aeruginosa</italic> combines increased efflux pump expression with down-regulation of <italic toggle="yes">OprD</italic> porin, leading to increased carbapenem resistance.<xref ref-type="bibr" rid="article-71616.r31">[31]</xref> OprD porin resistance to imipenem has also appeared in <italic toggle="yes">Enterobacter aerogenes</italic> and <italic toggle="yes">Klebsiella spp.</italic><xref ref-type="bibr" rid="article-71616.r34">[34]</xref></p>
      </sec>
      <sec id="article-71616.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>CRE infection can involve any site infected by <italic toggle="yes">Enterobacterales</italic> species, including the urinary tract, lungs, abdomen, surgical site, and bloodstream.&#x000a0;CRE infections and colonization are significant problems in hospitals and extended-care facilities.<xref ref-type="bibr" rid="article-71616.r35">[35]</xref> Long-term and varied antibiotic exposure increases the risk of bacterial resistance.<xref ref-type="bibr" rid="article-71616.r36">[36]</xref>&#x000a0;Clinicians should obtain a history of hospitalizations and residence in extended-care facilities, noting any history of antimicrobial treatment, which is essential information to collect during history taking to assess a patient's risk for CRE infections. Other risk factors include the presence of a urinary catheter and previous colonization with CRE.<xref ref-type="bibr" rid="article-71616.r36">[36]</xref> Patients hospitalized or in extended-care facilities with a history of CRE infection or colonization should be put under isolation precautions to limit the risk of the spread of CRE to other patients.<xref ref-type="bibr" rid="article-71616.r37">[37]</xref></p>
        <p>Carbapenem resistance does not confer increased pathogenicity, making initial presentation similar to other infections caused by a less resistant strain of the same organism. Therapeutic failure of empiric therapy may indicate a resistant organism, possibly CRE. Identification of CRE requires the identification of the organism and either susceptibility testing or molecular detection of resistance genes in the laboratory.<xref ref-type="bibr" rid="article-71616.r37">[37]</xref> As obtaining results can take several days, clinicians should prompt a change in empiric therapy if CRE is suspected.</p>
      </sec>
      <sec id="article-71616.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Phenotypic diagnosis requires bacterial culture and identification.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Disk diffusion, E-test, or automated susceptibility testing is done to identify the carbapenem resistance phenotype.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Determining the minimum inhibitory concentration (MIC) for carbapenems allows one to ascertain carbapenem resistance by comparing it to predetermined carbapenem breakpoints.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> The drawbacks of this process include the time required to perform this testing, usually several days, and the limited information obtained on specific resistance mechanisms.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> This becomes particularly relevant as although the MIC for carbapenems may fall within the susceptible range, a carbapenemase could still be present.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> If an isolate is suspected of harboring a carbapenemase due to susceptibility patterns, this should be confirmed with molecular testing.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref></p>
        <p>Another commonly employed phenotypic test is chromogenic media, which reacts and turns color in the presence of resistance enzymes produced by CRE.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref><xref ref-type="bibr" rid="article-71616.r38">[38]</xref> The Carba NP is also a cost-effective testing modality recommended for carbapenemase detection in <italic toggle="yes">Enterobacterales</italic>.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Performing the test typically takes a few minutes to 2 hours and has high sensitivity and specificity.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) is the newer technology for identifying CRE.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> This technique uses laser ionization of bacterial proteins to determine their molecular weight and create a proteomic profile.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Hydrolysis of carbapenems can be detected via a change in the molecular weight of the compounds, which can be detected by MALDI-TOF and extrapolated to identify CRE status.<xref ref-type="bibr" rid="article-71616.r38">[38]</xref>&#x000a0;This method is demonstrated to have 98.9% and 97.1% sensitivity and specificity, respectively.<xref ref-type="bibr" rid="article-71616.r38">[38]</xref> Cost, lack of access to MALDI-TOF units, and relative newness of this method are the most significant barriers to further utilization of this diagnostic modality.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> The modified Hodge test, which detects the amount of carbapenem left in agar in the presence of a suspected carbapenemase producer, is no longer uniformly recommended as it has a low sensitivity for MBL-producing bacteria and has a high rate of both false positives and false negatives.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref></p>
        <p>Molecular identification can be performed in hours and quickly determine the type of resistance mechanism involved.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> However, this method indicates the presence of a resistance gene and does not give susceptibility testing results.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Early detection of CRE infections helps to narrow down the best treatments and decrease the likelihood of spreading the infection. The most common modality of detection is multiplex PCR and microarray technologies.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Multiple PCR panels are commercially available.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref> Although these tests quickly determine the presence of pre-selected resistance genes, not all genes that confer resistance are available on these panels, and they are not used extensively due to the cost of these tests.<xref ref-type="bibr" rid="article-71616.r14">[14]</xref></p>
        <p>The decision on which testing modality to employ is determined by the resources of the individual laboratory and the clinical picture, which determines the urgency of diagnosis. Available susceptibilities typically suggest CRE, and confirmatory testing, such as a Carba NP test or molecular identification, is employed for further information. In more critical situations, a combination of phenotypic and molecular identification tests can be utilized simultaneously so empiric therapy can be appropriately tailored once susceptibility testing is available.</p>
      </sec>
      <sec id="article-71616.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment of CRE depends on the infection site, the isolated pathogen, the resistance profile, and species-specific native resistances&#x000a0;(see <bold>Table</bold><bold>.&#x000a0;</bold>Intrinsic Drug Resistance). Due to the complexity and variability of possible treatments, plans should be driven by <italic toggle="yes">in vitro</italic> susceptibility testing.<xref ref-type="bibr" rid="article-71616.r39">[39]</xref> The duration of therapy should be directed by guidelines relating to the specific infection being treated. Additionally, infectious disease specialists and microbiologists should be consulted for further recommendations. Antibiotics that may have activity against CRE include carbapenems, cefiderocol, a siderophore cephalosporin,&#x000a0;polymyxins, aminoglycosides, tigecycline, fluoroquinolones, trimethoprim-sulfamethoxazole, and beta-lactam/beta-lactamase inhibitors (BLBLI).<xref ref-type="bibr" rid="article-71616.r40">[40]</xref><xref ref-type="bibr" rid="article-71616.r41">[41]</xref><xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
        <p>
<bold>Uncomplicated Cystitis</bold>
</p>
        <p>For uncomplicated cystitis, trimethoprim/sulfamethoxazole, nitrofurantoin,&#x000a0; a dose of an aminoglycoside, or a fluoroquinolone (eg, ciprofloxacin or levofloxacin) are recommended if susceptible.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Fosfomycin could be considered in <italic toggle="yes">E. coli</italic> CRE isolates.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> If meropenem MIC is &#x02264;1 and carbapenemase testing is negative or unavailable, meropenem can be used as it is unlikely that a carbapenemase is present when meropenem susceptibility is preserved.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> If other agents are resistant and the isolate is not susceptible to meropenem or a carbapenemase is present, other agents such as ceftazidime-avibactam, imipenem-cilastatin-relebactam, cefiderocol, or meropenem-vaborbactam should be used, guided by susceptibility testing.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref>&#x000a0;Colistin should be considered if no other option is available.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
        <p>
<bold>Complicated Urinary Tract Infections</bold>
</p>
        <p>Complicated urinary tract infections (cUTI) with CRE usually affect patients with recurrent UTIs who have had repeated exposure to multiple antibiotics. Susceptibility and urine drug concentrations should drive effective antibiotic therapy. Fluoroquinolones and trimethoprim-sulfamethoxazole are preferred therapies for cUTI if susceptible.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> In isolates with a meropenem MIC &#x02264;1, extended infusion meropenem may be considered in isolates without a carbapenemase or when carbapenemase testing is unavailable.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Otherwise,&#x000a0;other agents such as ceftazidime-avibactam, imipenem-cilastatin-relebactam, cefiderocol, or meropenem-vaborbactam should be used, as guided by susceptibility testing.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Aminoglycoside therapy could additionally be considered while monitoring for nephrotoxicity.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
        <p>
<bold>Infections Outside the Urinary Tract</bold>
</p>
        <p>Infections outside the urinary tract with meropenem MICs &#x02264;1, no carbapenemase noted, or no carbapenemase testing is unavailable should be treated with extended-infusion meropenem.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> If the meropenem cannot be used, ceftazidime-avibactam therapy is recommended.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
        <p>In meropenem-resistant infections, ceftazidime-avibactam, imipenem-cilastatin-relebactam, or meropenem-vaborbactam can be used.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> If the patient has received medical care in an area of the world that has a high prevalence of metallo-beta-lactamases or has been previously infected or colonized, either ceftazidime-avibactam plus aztreonam or cefiderocol is recommended if carbapenemase testing is unavailable due to increased risk for a metallo-beta-lactamase.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Previously, combination therapy with polymixins and aminoglycosides was recommended, but this is no longer recommended due to the severe nephrotoxicity of this regimen.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Effective BLBLIs and cefiderocol have been developed that have better side effect profiles.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
        <p>
<bold>Carbapenemase-producing <italic toggle="yes">Enterobacterales</italic></bold>
</p>
        <p>For carbapenemase-producing isolates outside of the urinary tract, the recommended treatment differs based on the carbapenemase present. For KPC isolates, either ceftazidime-avibactam, imipenem-cilastatin-relebactam, or meropenem-vaborbactam is recommended.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref>&#x000a0;However, for metallo-beta-lactamase producers, cefiderocol or ceftazidime-avibactam plus aztreonam is recommended.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> BLBLIs (eg, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam) are ineffective against metallo-beta-lactamase producers.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref>&#x000a0;Conversely, aztreonam is typically effective.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Combining treatment with ceftazidime-avibactam and aztreonam is recommended as ESBL-producing isolates and OXA-48-like carbapenemases often coexist in metallo-beta-lactamase producers.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> For OXA-48-like carbapenemases, ceftazidime-avibactam is preferred, with cefiderocol as an alternative agent.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
        <p>Tigecycline and eravacycline could be considered alternative agents in patients with isolates that are not susceptible to beta-lactams or have contraindications to them.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref> Still, they should not be used as monotherapy for bloodstream infections or urinary infections due to low serum and urinary concentrations.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref>&#x000a0;Additionally, tigecycline has been shown to have increased mortality when used for monotherapy for severe infections.<xref ref-type="bibr" rid="article-71616.r42">[42]</xref>&#x000a0;Colistin and other polymixins are not recommended for infections other than uncomplicated cystitis.<xref ref-type="bibr" rid="article-71616.r40">[40]</xref></p>
      </sec>
      <sec id="article-71616.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Possible causes of carbapenem antibiotic resistance:</p>
        <list list-type="bullet">
          <list-item>
            <p>Carbapenemase production</p>
          </list-item>
          <list-item>
            <p>Decreased porin expression</p>
          </list-item>
          <list-item>
            <p>Increased efflux pump action&#x000a0;<xref ref-type="bibr" rid="article-71616.r43">[43]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-71616.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The severity of the infection determines the prognosis of the patient. Prognosis can be adversely affected if access to an effective antibiotic is absent or limited. Effective antibiotics tend to be newer and more expensive, limiting access to therapy.</p>
      </sec>
      <sec id="article-71616.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications that result from antibiotic resistance include severe illnesses, adverse effects secondary to medical treatments, and death. A complicating factor during the diagnosis and treatment of CRE infections is identifying resistance to previously discussed drug regimens. Commonly induced resistance mechanisms in CRE to other active antimicrobials include aminoglycosides, fosfomycin, and BLBLI.&#x000a0;Acquiring a single-point mutation in the 16S rRNA methyltransferase leads to resistance of all aminoglycosides.<xref ref-type="bibr" rid="article-71616.r44">[44]</xref>&#x000a0;This mutation can occur <italic toggle="yes">de novo</italic> or in combination with other resistance mechanisms and is best studied in NDM carbapenemase-producing CRE but can also be present in many other carbapenemase producers.<xref ref-type="bibr" rid="article-71616.r45">[45]</xref> This mutation can develop in the setting of aminoglycoside use and confers resistance. Fosfomycin resistance is common in <italic toggle="yes">E.coli, </italic>but many other <italic toggle="yes">Enterobacterales</italic>, including ESBL and CRE, do not demonstrate resistance. The development of resistance makes treating these infections more challenging. Resistance to this drug is typically seen by selecting resistant microbes through fosfomycin monotherapy.<xref ref-type="bibr" rid="article-71616.r46">[46]</xref>&#x000a0;Ceftazidime-avibactam is generally used for OXA-48 and KPC CRE, but when resistance appears among these isolates, mutations in <italic toggle="yes">bla<sub>Oxa48</sub></italic> and <italic toggle="yes">bla<sub>KPC</sub></italic> induce resistance, respectively.<xref ref-type="bibr" rid="article-71616.r47">[47]</xref></p>
      </sec>
      <sec id="article-71616.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>For patients who demonstrate CRE infection, an infectious disease consult is necessary. Microbiologists should also be involved because specialized tests may need to be performed for definitive diagnosis and treatment planning.</p>
      </sec>
      <sec id="article-71616.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Any CRE infection is considered an urgent complication, and patients need to understand the risks of their disease. Patients also need to be counseled regarding the likelihood of being colonized with CRE after their initial infections. This adds complexity to their medical treatment, as they are at increased risk of passing CRE colonization or infection to others and are at increased general risk of infections in the future.<xref ref-type="bibr" rid="article-71616.r48">[48]</xref> Infection prevention practices such as contact isolation should be employed with CRE infection or colonization patients.<xref ref-type="bibr" rid="article-71616.r49">[49]</xref></p>
      </sec>
      <sec id="article-71616.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>CRE outbreaks are usually uncommon and isolated to institutional or geographic regions. The prevalence of community-acquired CRE has been reported to be 0%&#x000a0;to 29.5%, and early screening detection of CRE colonization in patients can help prevent or limit outbreaks via proper isolation methods.<xref ref-type="bibr" rid="article-71616.r12">[12]</xref> Long-term care facilities have been shown to have lower rates of CRE than acute care hospitals, but this may be due to poor detection and surveillance methods.<xref ref-type="bibr" rid="article-71616.r50">[50]</xref>&#x000a0;Any healthcare facility should be aware of the risk CRE poses to patients and should take part in regular institutional, local, and national surveillance. An epidemiological assessment should accompany any case of CRE into etiology to limit further spread.</p>
        <p>An interprofessional team approach is critical when caring for patients with CRE infections. An infectious disease specialist, as well as an infectious disease board-certified pharmacist, can help to direct appropriate antimicrobial therapy. Infection control personnel are crucial team members as they quickly ensure that contact precautions are appropriately implemented and that patients are promptly isolated to protect other hospitalized patients. Laboratory personnel, who are well-trained on when to suspect CRE and the appropriate testing to perform, play a crucial role. However, bedside nurses are among the most pivotal team members because they are responsible for correctly administering antimicrobial therapy and ensuring that contact precautions are followed by hospital personnel and visitors. They also help to provide crucial education to patients and their family members. As the team plays its role, it ensures that the patient and other hospitalized patients get the care and that the risk of hospital-acquired infections is minimized.</p>
      </sec>
      <sec id="article-71616.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=71616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=71616">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/carbapenem-resistant-enterobacterales/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=71616">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/71616/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=71616">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-71616.s16">
        <fig id="article-71616.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Intrinsic Drug Resistance Contributed by Hayden Smith, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Table__1_screenshot" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-71616.s17">
        <fig id="article-71616.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Carbapenemase Ambler Classes Contributed by Caitlyn Hollingshead, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Carbapenemase__Diagramx1x" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-71616.s18">
        <title>References</title>
        <ref id="article-71616.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Multidrug-Resistant Bacteria in the Community: An Update.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>709</fpage>
            <page-range>709-722</page-range>
            <pub-id pub-id-type="pmid">33011046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darby</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Trampari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siasat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaya</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Alav</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Webber</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>JMA</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of antibiotic resistance revisited.</article-title>
            <source>Nat Rev Microbiol</source>
            <year>2023</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>280</fpage>
            <page-range>280-295</page-range>
            <pub-id pub-id-type="pmid">36411397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Tawfiq</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Momattin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Al-Ali</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Eljaaly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tirupathi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Haradwala</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Areti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alhumaid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rabaan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Al Mutair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schlagenhauf</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics in the pipeline: a literature review (2017-2020).</article-title>
            <source>Infection</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>553</fpage>
            <page-range>553-564</page-range>
            <pub-id pub-id-type="pmid">34606056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munita</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Antibiotic Resistance.</article-title>
            <source>Microbiol Spectr</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">27227291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacoby</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>AmpC beta-lactamases.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <page-range>161-82, Table of Contents</page-range>
            <pub-id pub-id-type="pmid">19136439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2023</year>
            <month>Jul</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">37463564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vardakas</surname>
                <given-names>KZ</given-names>
              </name>
              <name>
                <surname>Tansarli</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Rafailidis</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum &#x003b2;-lactamases: a systematic review and meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>67</volume>
            <issue>12</issue>
            <fpage>2793</fpage>
            <page-range>2793-803</page-range>
            <pub-id pub-id-type="pmid">22915465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verdino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soriente</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marabotti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Jan</month>
            <day>09</day>
            <volume>22</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33435500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spellberg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Leveraging antimicrobial stewardship into improving rates of carbapenem-resistant Enterobacteriaceae.</article-title>
            <source>Virulence</source>
            <year>2017</year>
            <month>May</month>
            <day>19</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-390</page-range>
            <pub-id pub-id-type="pmid">27187821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tzouvelekis</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Markogiannakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Psichogiou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tassios</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Daikos</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>682</fpage>
            <page-range>682-707</page-range>
            <pub-id pub-id-type="pmid">23034326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munoz-Price</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Poirel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Schwaber</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Daikos</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Cormican</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cornaglia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gniadkowski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayden</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Kumarasamy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Livermore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Maya</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Nordmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Pitout</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Villegas</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Woodford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>785</fpage>
            <page-range>785-96</page-range>
            <pub-id pub-id-type="pmid">23969216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Codjoe</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Donkor</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Carbapenem Resistance: A Review.</article-title>
            <source>Med Sci (Basel)</source>
            <year>2017</year>
            <month>Dec</month>
            <day>21</day>
            <volume>6</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29267233</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hammoudi Halat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ayoub Moubareck</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2020</year>
            <month>Apr</month>
            <day>16</day>
            <volume>9</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">32316342</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rabaan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Eljaaly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alhumaid</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Albayat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Al-Adsani</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sabour</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alshiekheid</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Al-Jishi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Khamis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alwarthan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alhajri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alfaraj</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Tombuloglu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Garout</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alabdullah</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>EAE</given-names>
              </name>
              <name>
                <surname>Yami</surname>
                <given-names>FSA</given-names>
              </name>
              <name>
                <surname>Almuhtaresh</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Livias</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Mutair</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Almushrif</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Abusalah</surname>
                <given-names>MAHA</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>An Overview on Phenotypic and Genotypic Characterisation of Carbapenem-Resistant <italic>Enterobacterales</italic>.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2022</year>
            <month>Nov</month>
            <day>19</day>
            <volume>58</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">36422214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsik</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Nambiar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Review of carbapenemases and AmpC-beta lactamases.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>30</volume>
            <issue>12</issue>
            <fpage>1094</fpage>
            <page-range>1094-5</page-range>
            <pub-id pub-id-type="pmid">22105420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boyd</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Livermore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Metallo-&#x003b2;-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2020</year>
            <month>Sep</month>
            <day>21</day>
            <volume>64</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">32690645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirvonen</surname>
                <given-names>VHA</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van der Kamp</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial Resistance Conferred by OXA-48 &#x003b2;-Lactamases: Towards a Detailed Mechanistic Understanding.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2021</year>
            <month>May</month>
            <day>18</day>
            <volume>65</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">33753332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>The global epidemiology of carbapenemase-producing Enterobacteriaceae.</article-title>
            <source>Virulence</source>
            <year>2017</year>
            <month>May</month>
            <day>19</day>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>460</fpage>
            <page-range>460-469</page-range>
            <pub-id pub-id-type="pmid">27593176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cui</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy.</article-title>
            <source>Front Microbiol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1823</fpage>
            <pub-id pub-id-type="pmid">31481937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Livermore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nicolau</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Meunier</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology.</article-title>
            <source>Clin Infect Dis</source>
            <year>2020</year>
            <month>Oct</month>
            <day>23</day>
            <volume>71</volume>
            <issue>7</issue>
            <fpage>1776</fpage>
            <page-range>1776-1782</page-range>
            <pub-id pub-id-type="pmid">32025698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poirel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Benouda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nordmann</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Emergence of NDM-1-producing Klebsiella pneumoniae in Morocco.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>66</volume>
            <issue>12</issue>
            <fpage>2781</fpage>
            <page-range>2781-3</page-range>
            <pub-id pub-id-type="pmid">21930570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Potter</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>D'Souza</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Dantas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The rapid spread of carbapenem-resistant Enterobacteriaceae.</article-title>
            <source>Drug Resist Updat</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>29</volume>
            <fpage>30</fpage>
            <page-range>30-46</page-range>
            <pub-id pub-id-type="pmid">27912842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haeili</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barmudeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Omrani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zeinalzadeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kafil</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Batignani</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghodousi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cirillo</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Whole-genome sequence analysis of clinically isolated carbapenem resistant Escherichia coli from Iran.</article-title>
            <source>BMC Microbiol</source>
            <year>2023</year>
            <month>Feb</month>
            <day>27</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <pub-id pub-id-type="pmid">36850019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Thom</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kristie Johnson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Emergence of Klebsiella pneumoniae carbapenemase-producing bacteria.</article-title>
            <source>South Med J</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>104</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-5</page-range>
            <pub-id pub-id-type="pmid">21119555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salamzade</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Brennan-Krohn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Worby</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Shea</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Howe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Wurster</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Delaney</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kanjilal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Onderdonk</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bittencourt</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gussin</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Ferraro</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Shenoy</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Cuomo</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Cosimi</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Pierce</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Bhattacharyya</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Earl</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Inter-species geographic signatures for tracing horizontal gene transfer and long-term persistence of carbapenem resistance.</article-title>
            <source>Genome Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>05</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">35379360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The penicillins.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>290</fpage>
            <page-range>290-307</page-range>
            <pub-id pub-id-type="pmid">10090000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tooke</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Hinchliffe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bragginton</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Colenso</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Hirvonen</surname>
                <given-names>VHA</given-names>
              </name>
              <name>
                <surname>Takebayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;-Lactamases and &#x003b2;-Lactamase Inhibitors in the 21st Century.</article-title>
            <source>J Mol Biol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>23</day>
            <volume>431</volume>
            <issue>18</issue>
            <fpage>3472</fpage>
            <page-range>3472-3500</page-range>
            <pub-id pub-id-type="pmid">30959050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gustaferro</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Cephalosporin antimicrobial agents and related compounds.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1991</year>
            <month>Oct</month>
            <volume>66</volume>
            <issue>10</issue>
            <fpage>1064</fpage>
            <page-range>1064-73</page-range>
            <pub-id pub-id-type="pmid">1921490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papp-Wallace</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Endimiani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taracila</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Carbapenems: past, present, and future.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>55</volume>
            <issue>11</issue>
            <fpage>4943</fpage>
            <page-range>4943-60</page-range>
            <pub-id pub-id-type="pmid">21859938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Karim</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Structural basis for carbapenem-hydrolyzing mechanisms of carbapenemases conferring antibiotic resistance.</article-title>
            <source>Int J Mol Sci</source>
            <year>2015</year>
            <month>Apr</month>
            <day>29</day>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>9654</fpage>
            <page-range>9654-92</page-range>
            <pub-id pub-id-type="pmid">25938965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lepe</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Resistance mechanisms in Gram-negative bacteria.</article-title>
            <source>Med Intensiva (Engl Ed)</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>46</volume>
            <issue>7</issue>
            <fpage>392</fpage>
            <page-range>392-402</page-range>
            <pub-id pub-id-type="pmid">35660283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franco</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Caiaffa-Filho</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Burattini</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa in a Brazilian university hospital.</article-title>
            <source>Clinics (Sao Paulo)</source>
            <year>2010</year>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>825</fpage>
            <page-range>825-9</page-range>
            <pub-id pub-id-type="pmid">21049207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Are</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Pesapane</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muresu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cossu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dettori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mura</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Cocuzza</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aliberti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piana</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study.</article-title>
            <source>J Hosp Infect</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>413</fpage>
            <page-range>413-418</page-range>
            <pub-id pub-id-type="pmid">29621600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doumith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ellington</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Livermore</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Woodford</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>659</fpage>
            <page-range>659-67</page-range>
            <pub-id pub-id-type="pmid">19233898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Jean</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Hsueh</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Carbapenem-Resistant Enterobacterales in Long-Term Care Facilities: A Global and Narrative Review.</article-title>
            <source>Front Cell Infect Microbiol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>601968</fpage>
            <pub-id pub-id-type="pmid">33968793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez-Galera</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bravo-Ferrer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Paniagua</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kostyanev</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>de Kraker</surname>
                <given-names>MEA</given-names>
              </name>
              <name>
                <surname>Feifel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sojo-Dorado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schotsman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cant&#x000f3;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Daikos</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Carevic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dragovac</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Raka</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hristea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Akova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reguera</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Valiente de Santis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Torre-Cisneros</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Roilides</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Radulovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirakli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Falagas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pintado</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goossens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bonten</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Guti&#x000e9;rrez</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rodriguez-Ba&#x000f1;o</surname>
                <given-names>J</given-names>
              </name>
              <collab>COMBACTE-CARE-EURECA Team</collab>
            </person-group>
            <article-title>Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA).</article-title>
            <source>EClinicalMedicine</source>
            <year>2023</year>
            <month>Mar</month>
            <volume>57</volume>
            <fpage>101871</fpage>
            <pub-id pub-id-type="pmid">36895801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zong</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhuo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <collab>Society of Bacterial Infection and Resistance of Chinese Medical Association</collab>
              <collab>Expert Committee on Clinical Use of Antimicrobial Agents and Evaluation of Antimicrobial Resistance of the National Health Commission</collab>
              <collab>Infectious Diseases Society of Chinese Medical Education Association</collab>
            </person-group>
            <article-title>Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli.</article-title>
            <source>J Microbiol Immunol Infect</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>653</fpage>
            <page-range>653-671</page-range>
            <pub-id pub-id-type="pmid">36868960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sparbier</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schubert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weller</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Boogen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kostrzewa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based functional assay for rapid detection of resistance against &#x003b2;-lactam antibiotics.</article-title>
            <source>J Clin Microbiol</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>927</fpage>
            <page-range>927-37</page-range>
            <pub-id pub-id-type="pmid">22205812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez-Ba&#x000f1;o</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cisneros</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gudiol</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of infections caused by carbapenemase-producing Enterobacteriaceae.</article-title>
            <source>Enferm Infecc Microbiol Clin</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>32 Suppl 4</volume>
            <fpage>49</fpage>
            <page-range>49-55</page-range>
            <pub-id pub-id-type="pmid">25542052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum &#x003b2;-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Aug</month>
            <day>25</day>
            <volume>75</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <page-range>187-212</page-range>
            <pub-id pub-id-type="pmid">35439291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kazmierczak</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Hackel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Echols</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sahm</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-&#x003b2;-lactamase-producing isolates (SIDERO-WT-2014 Study).</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-184</page-range>
            <pub-id pub-id-type="pmid">30395986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yahav</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lador</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leibovici</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of tigecycline: a systematic review and meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>66</volume>
            <issue>9</issue>
            <fpage>1963</fpage>
            <page-range>1963-71</page-range>
            <pub-id pub-id-type="pmid">21685488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meletis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Carbapenem resistance: overview of the problem and future perspectives.</article-title>
            <source>Ther Adv Infect Dis</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-21</page-range>
            <pub-id pub-id-type="pmid">26862399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wachino</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Arakawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>523</fpage>
            <page-range>523-537</page-range>
            <pub-id pub-id-type="pmid">27208771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Miao</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>ZK</given-names>
              </name>
              <name>
                <surname>Sheng</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese University Hospital.</article-title>
            <source>BMC Infect Dis</source>
            <year>2012</year>
            <month>Dec</month>
            <day>23</day>
            <volume>12</volume>
            <fpage>373</fpage>
            <pub-id pub-id-type="pmid">23259910</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karageorgopoulos</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Miriagou</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tzouvelekis</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Spyridopoulou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Daikos</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>67</volume>
            <issue>11</issue>
            <fpage>2777</fpage>
            <page-range>2777-9</page-range>
            <pub-id pub-id-type="pmid">22782489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Both</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ttner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Perbandt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Belmar Campos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Kluge</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aepfelbacher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wichmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>72</volume>
            <issue>9</issue>
            <fpage>2483</fpage>
            <page-range>2483-2488</page-range>
            <pub-id pub-id-type="pmid">28637339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hassoun-Kheir</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hussien</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Karram</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saffuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Badaan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peleg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aboelhega</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Warman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pollak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szwarcwort Cohen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance and burden of carbapenem-resistant Enterobacterales (CRE) colonization acquisition in hospitalized patients.</article-title>
            <source>Antimicrob Resist Infect Control</source>
            <year>2023</year>
            <month>Nov</month>
            <day>20</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>129</fpage>
            <pub-id pub-id-type="pmid">37986092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mills</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Marchaim</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Multidrug-Resistant Gram-Negative Bacteria: Infection Prevention and Control Update.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>969</fpage>
            <page-range>969-994</page-range>
            <pub-id pub-id-type="pmid">34752228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71616.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gniadek</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Simner</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Carbapenem-Resistant Non-Glucose-Fermenting Gram-Negative Bacilli: the Missing Piece to the Puzzle.</article-title>
            <source>J Clin Microbiol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>1700</fpage>
            <page-range>1700-1710</page-range>
            <pub-id pub-id-type="pmid">26912753</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
